Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Gerald J. Harris, MD
Healthcare Professional Professor
Froedtert and Medical
College of Wisconsin
925 North 87th Street
Milwaukee, Wisconsin, United States
Gerald J. Harris is Professor of ophthalmology and Chief of orbital and ophthalmic plastic surgery at the Froedtert and the Medical College of Wisconsin Eye Institute. He was born in Philadelphia, received his medical degree and ophthalmology training at Northwestern University and was a fellow in orbital and oculoplastic surgery at Columbia University. He served as a U.S. Air Force flight surgeon in Southeast Asia.
With a primary commitment to the surgical care of his patients, Dr. Harris has made scholarly contributions in the areas of orbital disease, eyelid reconstruction and lacrimal surgery. His publications include more than 150 original articles and book chapters as well as the surgical text of Atlas of Oculofacial Reconstruction.
Dr. Harris is editor emeritus of Ophthalmic Plastic and Reconstructive Surgery, having served as editor-in-chief for eight years. He is a member of the Orbital Society and the American Ophthalmological Society and is in the Presidential Track of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS), serving as vice president in 2015, president-elect in 2016, president in 2017, and chair of the advisory board in 2018. Dr. Harris is the Program Director and Principal Preceptor of an American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) accredited fellowship training program.
Representative Publications:
The Role of the Immune Response in the Pathogenesis of Thyroid Eye Disease: A Reassessment
Teprotumumab for Thyroid-Associated Ophthalmopathy
Herpes Zoster Ophthalmicus With Orbital Findings Preceding Skin Rash
Mechanisms of Visual Loss in Severe Proptosis
Related Content
-
Vivek R. Patel, MDVivek R. Patel, MD, received his undergr...
-
Wills Eye HospitalWills Eye Hospital, located in Philadelp...
-
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active ...Horizon Pharma plc today announced topli...
-
What Is Thyroid Eye Disease (TED)?https://www.youtube.com/watch?v=OVUZcQWF...
-
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
-
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...
-
Update on Graves’ Disease: Advances in Treatment of Mild, Moderate and Severe Thyroid Eye DiseasePurpose of Review: To report the most r...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.